| Index | - | P/E | - | EPS (ttm) | -3.49 | Insider Own | 3.73% | Shs Outstand | 134.20M | Perf Week | 6.61% |
| Market Cap | 22.69B | Forward P/E | - | EPS next Y | -2.13 | Insider Trans | -18.01% | Shs Float | 128.76M | Perf Month | -4.18% |
| Enterprise Value | 23.31B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 9.25% | Perf Quarter | 16.23% |
| Income | -453.00M | P/S | 19.18 | EPS this Y | - | Inst Trans | - | Short Ratio | 5.79 | Perf Half Y | 90.17% |
| Sales | 1.18B | P/B | - | EPS next Y | - | ROA | -23.71% | Short Interest | 11.92M | Perf YTD | 65.54% |
| Book/sh | -1.66 | P/C | 21.55 | EPS next 5Y | - | ROE | 211.46% | 52W High | 191.05 -11.50% | Perf Year | 148.54% |
| Cash/sh | 7.85 | P/FCF | - | EPS past 3/5Y | - | ROIC | -29.30% | 52W Low | 66.59 153.91% | Perf 3Y | 519.11% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 29.71% 27.89% | Gross Margin | 65.01% | Volatility | 5.71% 4.94% | Perf 5Y | 62.20% |
| Dividend TTM | - | EV/Sales | 19.70 | EPS Y/Y TTM | 1.97% | Oper. Margin | -39.75% | ATR (14) | 8.67 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.71 | Sales Y/Y TTM | 60.08% | Profit Margin | -38.33% | RSI (14) | 51.84 | Recom | 2.06 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.03 | EPS Q/Q | -12.50% | SMA20 | 0.14% | Beta | 1.70 | Target Price | 202.40 |
| Payout | 0.00% | Debt/Eq | 8.34 | Sales Q/Q | 44.40% | SMA50 | 0.67% | Rel Volume | 0.84 | Prev Close | 162.94 |
| Employees | 2,498 | LT Debt/Eq | -16.99 | Earnings | Nov 05 | SMA200 | 31.36% | Avg Volume | 1.97M | Price | 169.08 |
| IPO Date | Oct 04, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -18.14% 6.60% | Net Debt/EBITDA | -1.57 | Volume | 1,661,448 | Change | 3.77% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-07-26 | Reiterated | Barclays | Overweight | $200 → $220 |
| Oct-01-26 | Reiterated | Guggenheim | Buy | $190 → $200 |
| Sep-10-26 | Reiterated | Bernstein | Outperform | $200 → $210 |
| Sep-09-26 | Reiterated | UBS | Buy | $150 → $225 |
| Sep-08-26 | Initiated | Rothschild & Co Redburn | Buy | $203 |
| Aug-04-26 | Reiterated | Piper Sandler | Overweight | $127 → $193 |
| Aug-04-26 | Reiterated | Morgan Stanley | Overweight | $175 → $185 |
| Aug-04-26 | Reiterated | Stephens & Co. | Overweight | $99 → $195 |
| Jul-31-26 | Reiterated | RBC Capital | Outperform | $185 → $210 |
| Jul-31-26 | Reiterated | Stifel Nicolaus | $130 → $180 |
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,183 | 982 | 739 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 414 | 349 | 290 | — | — | — | — | — | — | |
| Gross Profit | 770 | 633 | 449 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 864 | 706 | 545 | — | — | — | — | — | — | |
| Research and Development | 376 | 364 | 348 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | -470 | -437 | -444 | — | — | — | — | — | — | |
| Interest Expense | 4 | 4 | 3 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 21 | 24 | 11 | — | — | — | — | — | — | |
| Net Income Before Taxes | -455 | -418 | -435 | — | — | — | — | — | — | |
| Income Taxes | -2 | -1 | 1 | — | — | — | — | — | — | |
| Consolidated Net Income | -453 | -416 | -436 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -453 | -416 | -436 | — | — | — | — | — | — | |
| Net Income | -453 | -416 | -436 | — | — | — | — | — | — | |
| EPS (Recurring) | -3.49 | -3.32 | -3.56 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.49 | -3.32 | -3.56 | — | — | — | — | — | — | |
| EPS (Diluted) | -3.49 | -3.32 | -3.56 | — | — | — | — | — | — | |
| EBITDA | -411 | -374 | -390 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 18.87 | 13.00 | 5.08 | — | — | — | — | — | — | |
| Gross Margin | 65.09 | 64.46 | 60.76 | — | — | — | — | — | — | |
| Operating Margin | -39.73 | -44.50 | -60.08 | — | — | — | — | — | — | |
| Net Margin | -38.29 | -42.36 | -59.00 | — | — | — | — | — | — | |
| Shares Outstanding | 132 | 125 | 123 | — | — | — | — | — | — | |
| Market Capitalization | 22,319 | 12,768 | 3,758 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| MIGNONE ROBERTO | Director | Oct 21 '26 | Option Exercise | 0.00 | 264 | 0 | 10,538 | Oct 22 |
| Hidalgo Medina Manuel | Director | Oct 17 '26 | Option Exercise | 0.00 | 232 | 0 | 5,252 | Oct 19 |
| Tariq Musa | Director | Oct 16 '26 | Sale | 165.88 | 116 | 19,242 | 11,583 | Oct 19 |
| Tariq Musa | Director | Oct 15 '26 | Option Exercise | 0.00 | 250 | 0 | 11,699 | Oct 19 |
| Azar Alex M II | Director | Oct 14 '26 | Sale | 159.89 | 69 | 11,032 | 893 | Oct 15 |
| Azar Alex M II | Director | Oct 12 '26 | Option Exercise | 0.00 | 137 | 0 | 962 | Oct 13 |
| Saia John G. | Chief Legal Officer | Oct 01 '26 | Option Exercise | 0.00 | 7,063 | 0 | 46,054 | Oct 02 |
| Monroe Terilyn J. | Chief People Officer | Oct 01 '26 | Option Exercise | 0.00 | 4,019 | 0 | 26,998 | Oct 02 |
| Kalia Kumud | Chief Information Officer | Oct 01 '26 | Option Exercise | 0.00 | 6,046 | 0 | 45,840 | Oct 02 |
| Freeman Chris | Chief Commercial Officer | Oct 01 '26 | Option Exercise | 0.00 | 7,416 | 0 | 72,790 | Oct 02 |
| Chudova Darya | Chief Technology Officer | Oct 01 '26 | Option Exercise | 0.00 | 8,033 | 0 | 78,668 | Oct 02 |
| Bell Michael Brian | Chief Financial Officer | Oct 01 '26 | Option Exercise | 0.00 | 7,280 | 0 | 59,096 | Oct 02 |
| Talasaz AmirAli | Co-Chief Executive Officer | Oct 01 '26 | Option Exercise | 0.00 | 33,713 | 0 | 1,859,453 | Oct 02 |
| Eltoukhy Helmy | Co-Chief Executive Officer | Oct 01 '26 | Option Exercise | 0.00 | 33,713 | 0 | 1,976,036 | Oct 02 |
| Eltoukhy Helmy | Co-Chief Executive Officer | Sep 30 '26 | Option Exercise | 0.00 | 2,817 | 0 | 1,943,751 | Oct 02 |